migalastat
Sign in to saveAlso known as 1-deoxygalactonojirimycin
Migalastat, sold under the brand name Galafold, is a medication used for the treatment of Fabry disease, a rare genetic disorder. Migalastat is an alpha-galactosidase A (alpha-Gal A) pharmacological chaperone. It was developed by Amicus Therapeutics.
Key facts
- Drug.image
- 1-Deoxygalactonojirimycin.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 125
- Drug.pronounce
- mi GAL a stat
- Drug.tradename
- Galafold
- Drug.MedlinePlus
- a625101
- Drug.DailyMedID
- Migalastat
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- By mouth
- Drug.class
- Pharmacological chaperone
- Drug.ATC_prefix
- A16
- Drug.ATC_suffix
- AX14
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- JP: Rx-only
- Drug.bioavailability
- 75%
via Wikipedia infobox
~7 min read
Encyclopedic overview
11 sectionsContents
- Medical uses
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- History
- Society and culture
- Legal status
- References
Migalastat, sold under the brand name Galafold, is a medication used for the treatment of Fabry disease, a rare genetic disorder. Migalastat is an alpha-galactosidase A (alpha-Gal A) pharmacological chaperone. It was developed by Amicus Therapeutics.
The most common adverse drug reactions include headache, nasal and throat irritation (nasopharyngitis), urinary tract infection, nausea, and fever (pyrexia).
Excerpted from Wikipedia’s “migalastat” article, available under the CC BY-SA 4.0 licence.